Laura Howells

Laura Howells

Auto-generated profile, based on publicly available information

Laura Howells

Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
LHL.M. Howells
L.M. Howells
JCJ.R. Chalmers
J.R. Chalmers
SGS. Gran
S. Gran
AAA. Ahmed
A. Ahmed
CAC. Apfelbacher
C. Apfelbacher
KTK.S. Thomas
K.S. Thomas
Eczema control has been identified as an important outcome by key stakeholders in eczema research (including patients, carers, healthcare professionals and researchers) but no validated instruments for the domain have been identified. To develop a measurement instrument to capture a patient's perspective of eczema control that is suitable for use in eczema clinical trials. Best practice for the development of a patient-reported outcome was followed. A mixed-methods approach was used to develop and refine a conceptual framework, generate, refine and select items and to test the distribution and construct validity of the final scale. The mixed-methods approach involved expert panel meetings (including patient representatives, healthcare professionals and methodologists), and data collection using a focus group, cognitive interviews and an online survey with people with eczema and caregivers. Multivariable linear regression was used in the item selection process. Fourteen expert panel members co-produced the instrument, with input from people with eczema and caregivers via a focus group (n = 6), cognitive interviews (n = 13) and an online survey (n = 330). The resulting instrument, Recap of atopic eczema (RECAP), is a seven-item questionnaire that captures eczema control via self or caregiver report. The development process aimed to ensure good content validity and feasibility. Initial testing suggested no floor or ceiling effects and good construct validity. Hypothesized correlation with the Patient-Oriented Eczema Measure was confirmed [r(258) = 0·83, P < 0·001]. RECAP has the potential to improve reporting of eczema control in research and clinical practice. Further exploration of measurement properties is required. What's already known about this topic? Eczema control has been identified as an important outcome by key stakeholders in eczema research (including patients, carers, healthcare professionals and researchers). Qualitative studies suggest eczema control is a multifaceted and individual experience and no instrument has been identified that captures eczema control in this way. What does this study add? We have developed Recap of atopic eczema (RECAP), a seven-item questionnaire to capture the experience of eczema control in all ages and eczema severities; there are two versions: a self-reported version for adults and older children with eczema, and a caregiver-reported version for younger children with eczema. Designed with input from people with eczema, caregivers and healthcare professionals to ensure good content validity. Initial testing of score distributions and construct validity suggests good measurement properties. What are the clinical implications of the work? The RECAP instrument is appropriate and feasible for measuring eczema control in clinical trials and may also be useful in routine practice.

17 April 2018 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
LHL. Howells
L. Howells
SRS. Ratib
S. Ratib
JCJ. R. Chalmers
J. R. Chalmers
LBL. Bradshaw
L. Bradshaw
KTK. S. Thomas
K. S. Thomas
TTthe CLOTHES trial team
the CLOTHES trial team
The Patient Oriented Eczema Measure (POEM), scored 0-28, is the core outcome instrument recommended for measuring patient-reported atopic eczema symptoms in clinical trials. To date, two published studies have broadly concurred that the MIC of the POEM is 3 points. Further assessment of the minimally important change (MIC) of POEM in different populations, and using a variety of methods, will improve interpretability of the POEM in research and clinical practice. To calculate the smallest detectable change in the POEM and estimate the MIC of the POEM using a variety of methods in a trial dataset of children with moderate to severe atopic eczema. This study used distribution-based and anchor-based methods to calculate the MIC of the POEM in children with moderate to severe eczema. Data was collected from 300 children. The smallest detectable change was 2.12. The MIC estimates were 1.07 (0.2 SD) and 2.68 (0.5 SD) based on distribution-based methods, were 3.09 to 6.13 based on patient-reported anchor-based methods, and were 3.23 to 5.38 based on investigator-reported anchor-based methods. We recommend the following thresholds are used to interpret changes in POEM scores: ≤ 2, unlikely to be a change beyond measurement error; 2.1 to 2.9, a small change detected that is likely to be beyond measurement error but may not be clinically important; 3 to 3.9, probably a clinically important change; 4+, very likely to be a clinically important change.

29 May 2021 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
LHL. Howells
L. Howells
NLN. Lancasterm
N. Lancasterm
MMM. McPheem
M. McPheem
CBC. Bundy
C. Bundy
JIJohn R Ingram
John R Ingram
KTK.S. Thomas
K.S. Thomas
Background Although Hidradenitis Suppurativa (HS) is known to affect quality of life, little summative knowledge exists on how HS impacts people living with the condition. Aim to synthesise experiences of people with HS within published qualitative research. Methods Searches on databases MEDLINE, PsycINFO, EMBASE and CINHAL were conducted on 17th April 2020. Two independent reviewers screened 5512 publications. Study quality was assessed using the National Institute for Health and Care Excellence (NICE) quality appraisal checklist for qualitative studies. Thematic synthesis generated descriptive and analytic themes. Results Fourteen studies were included. Four studies fulfilled most quality criteria, eight studies fulfilled some quality criteria, and two studies fulfilled few quality criteria. There were three final themes. 1) Putting the brakes on life - The physical, psychological and social consequences of HS resulted in people missing out on multiple life events. This could have a cumulative effect that influences the trajectory of someone’s life. 2) A stigmatised identity: concealed and revealed – People try to conceal their HS, visually and verbally, but this results anticipation and fear of exposure. Social support and psychological acceptance helped people cope. Connection with others with HS may have a specific role in preserving a positive self-identity. 3) falling through the cracks – Delayed diagnosis, misdiagnosis and lack of access to care were reported. People felt unheard and misunderstood by healthcare professionals, and healthcare interactions could enhance feelings of shame. Conclusions There needs to be improvements to clinical care to allow people with HS to live their life more fully.

15 November 2017 in BMJ Open
Verified
Journal Article
Open access
PDF file
LHLaura M Howells
Laura M Howells
JCJoanne R Chalmers
Joanne R Chalmers
FCFiona Cowdell
Fiona Cowdell
SRSonia Ratib
Sonia Ratib
MSMiriam Santer
Miriam Santer
KTKim S Thomas
Kim S Thomas
Objective To inform the development of a core outcome set for eczema by engaging with people with eczema and parents of children with eczema to understand their experiences and understanding of the concept ‘eczema control’. Design 37 participants took part in a total of six semi-structured online focus groups held in a typed chatroom with 5–7 participants per group. Three groups involved adults with eczema and three groups involved parents of children with eczema. Framework analysis was used for data analysis. Setting A community-based sample was recruited from across the UK via social media and email. Participants 19 adults aged 17–61 years (15/19 female, 16/19 white) and 18 parents of children with eczema aged 9 months–17 years (9/18 female, 18/19 white). Results Four main themes were identified:(1) ‘Commonalities and differences in the experiences of control’: a reduction in symptoms such as itch and sleep loss characterised eczema control, but what level was acceptable differed across participants;(2) ‘Eczema control goes beyond the skin’: psychological factors, social factors, the constant scratching and the impact on everyday activities are a variety of ways an individual can be impacted;(3) ‘Stepping up and down of treatment’: participants’ stepped-up treatment in response to loss of control, but several factors complicated this behaviour. Control needed to be maintained after stepped-up treatment ended to be acceptable; and (4) ‘How to measure control’: self-report was generally preferred to allow frequent measurements and to capture unobservable features. Although most thought their eczema needed to be measured frequently, many also felt that this was not always realistic or desirable. Conclusions ‘Eczema control’ is a complex experience for people with eczema and parents of children with the condition. These experiences could have important implications on how long-term control should be measured in eczema clinical trials and clinical practice.

7 July 2022 in British Journal of Dermatology
Verified
Journal Article
Open access
JBJonathan M. Batchelor
Jonathan M. Batchelor
SGSonia Gran
Sonia Gran
PLPaul Leighton
Paul Leighton
LHLaura Howells
Laura Howells
AMAlan A. Montgomery
Alan A. Montgomery
KTKim S. Thomas
Kim S. Thomas
Background: Validated outcome measures are needed for vitiligo trials. Objectives: To assess construct validity, interpretability, reliability and acceptability of the Vitiligo Noticeability Scale (VNS). Methods: We used images of vitiligo before and after treatment, plus outcome data, from the HI-Light Vitiligo trial. We compared outcome assessments made by trial participants with assessments of images by clinicians and people with vitiligo who were not trial participants [Patient and Public Involvement (PPI) panel]. Hypothesis testing assessed psychometric properties of the VNS, with κ statistics to assess agreement between outcomes. Three focus groups and two online discussion groups provided insight into the use of VNS by people with vitiligo. Results: Our hypothesis of a positive association between VNS and participant-reported global treatment success was supported for trial participants (κ = 0·41 if VNS success was defined as ≥ 4; κ = 0·71 if VNS success was defined as ≥ 3), but not for the blinded PPI panel (κ = 0·28). As hypothesized, the association with participant-reported global success was higher for VNS (κ = 0·41) than for clinician-reported percentage repigmentation (κ = 0·17). Seventy-five per cent of trial participants valued a VNS of 3 (partial response) as a treatment success. Test–retest reliability was good: κ = 0·69 (95% confidence interval 0·63–0·74). Age and skin phototype did not influence interpretation of the VNS scores. To people with vitiligo, the VNS is an acceptable and meaningful patient-reported outcome measure. Conclusions: Trial participants may assess their vitiligo differently compared with blinded assessors. A VNS score of 3 may be more highly valued by people undergoing vitiligo treatment than was previously thought. What is already known about this topic? Vitiligo is a common condition, and can have a considerable psychological impact.A Vitiligo Core Outcome Set is being developed, to enable the results of vitiligo trials to be compared and combined more easily.The Vitiligo Noticeability Scale (VNS) is a patient-reported outcome measure (PROM) developed in partnership with people with vitiligo; initial validation studies have been promising. What does this study add? The VNS shows good construct validity, reliability and acceptability; it can be used in all ages and skin phototypes.All five levels of the VNS scale should be reported for transparency, to aid interpretation of trial findings, and to facilitate meta-analysis in systematic reviews.VNS assessments made by trial participants and independent observers are likely to be qualitatively different, making blinded assessment of VNS by independent observers difficult to interpret.Blinding of participants to trial interventions is recommended whenever possible. What are the clinical implications of the work? The VNS can be used as a PROM to assess the cosmetic acceptability of repigmentation at individual patches of vitiligo.A VNS score of 3 or more is likely to be valued by patients as a treatment success.

5 February 2019 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
LHLaura Howells
Laura Howells
KTKim S Thomas
Kim S Thomas
ASAlison V Sears
Alison V Sears
INIbrahim Nasr
Ibrahim Nasr
AWAndreas Wollenberg
Andreas Wollenberg
TIthe long‐term control of eczema working group for the HOME initiative
the long‐term control of eczema working group for the HOME initiative
Background: Atopic eczema (also known as eczema) is a chronic, inflammatory skin condition that often afflicts patients’ health and well‐being. The Harmonising Outcome Measures for Eczema (HOME) initiative recommends that ‘long‐term control of eczema’ is measured in all clinical trials 3 months or longer in duration. However, little has been published on what eczema control means to those living with or treating atopic eczema.Objectives: To (i) develop understanding of what eczema control means to patients, carers and clinicians and (ii) explore the feasibility and acceptability of different ways of measuring eczema control in the long term.Methods: Online focus groups explored patients/carers experiences in the UK, the United States, the Netherlands, France, Sweden and Japan, and an international online survey gathered views of clinicians. The framework method was used to analyse the focus groups, and thematic analysis was used to analyse survey data. All findings were integrated into a theoretical framework to create overarching themes that cut across these diverse groups.Results: Eight focus groups with patients (16 years+) and eight groups with carers of children took place (N = 97). Sixty‐two people took part in the survey. Eczema control was described as a multifaceted construct involving changes in disease activity, the treatment and management of the condition and psychological, social and physical functioning. Patient/carer measurement allows personal accounts and frequent measurement, whilst clinician measurement was deemed less subjective. The burden on patients/carers and issues for analysing and interpreting data should be considered.Conclusions: This study formed the basis of judging the content validity and feasibility of measurement instruments/methods to assess control of eczema in clinical trials. This online approach to an international qualitative study is an example of how core outcome set developers with limited resources can engage with multiple stakeholder groups on an international basis to inform consensus meeting discussions.